205 related articles for article (PubMed ID: 24424270)
1. Tunable sustained intravitreal drug delivery system for daunorubicin using oxidized porous silicon.
Hou H; Nieto A; Ma F; Freeman WR; Sailor MJ; Cheng L
J Control Release; 2014 Mar; 178():46-54. PubMed ID: 24424270
[TBL] [Abstract][Full Text] [Related]
2. A sustained dual drug delivery system for proliferative vitreoretinopathy.
Xiao Y; Choi KS; Warther D; Huffman K; Landeros S; Freeman WR; Sailor MJ; Cheng L
Drug Deliv; 2020 Dec; 27(1):1461-1473. PubMed ID: 33100053
[TBL] [Abstract][Full Text] [Related]
3. Controlled Release of Dexamethasone From an Intravitreal Delivery System Using Porous Silicon Dioxide.
Hou H; Wang C; Nan K; Freeman WR; Sailor MJ; Cheng L
Invest Ophthalmol Vis Sci; 2016 Feb; 57(2):557-66. PubMed ID: 26882530
[TBL] [Abstract][Full Text] [Related]
4. Porous silicon oxide-PLGA composite microspheres for sustained ocular delivery of daunorubicin.
Nan K; Ma F; Hou H; Freeman WR; Sailor MJ; Cheng L
Acta Biomater; 2014 Aug; 10(8):3505-12. PubMed ID: 24793657
[TBL] [Abstract][Full Text] [Related]
5. Hydrosilylated porous silicon particles function as an intravitreal drug delivery system for daunorubicin.
Hartmann KI; Nieto A; Wu EC; Freeman WR; Kim JS; Chhablani J; Sailor MJ; Cheng L
J Ocul Pharmacol Ther; 2013 Jun; 29(5):493-500. PubMed ID: 23448595
[TBL] [Abstract][Full Text] [Related]
6. Surface engineering of porous silicon microparticles for intravitreal sustained delivery of rapamycin.
Nieto A; Hou H; Moon SW; Sailor MJ; Freeman WR; Cheng L
Invest Ophthalmol Vis Sci; 2015 Jan; 56(2):1070-80. PubMed ID: 25613937
[TBL] [Abstract][Full Text] [Related]
7. Intravitreal controlled release of dexamethasone from engineered microparticles of porous silicon dioxide.
Wang C; Hou H; Nan K; Sailor MJ; Freeman WR; Cheng L
Exp Eye Res; 2014 Dec; 129():74-82. PubMed ID: 25446320
[TBL] [Abstract][Full Text] [Related]
8. Oxidized porous silicon particles covalently grafted with daunorubicin as a sustained intraocular drug delivery system.
Chhablani J; Nieto A; Hou H; Wu EC; Freeman WR; Sailor MJ; Cheng L
Invest Ophthalmol Vis Sci; 2013 Feb; 54(2):1268-79. PubMed ID: 23322571
[TBL] [Abstract][Full Text] [Related]
9. Porous silicon based intravitreal platform for dual-drug loading and controlled release towards synergistic therapy.
Warther D; Xiao Y; Li F; Wang Y; Huffman K; Freeman WR; Sailor M; Cheng L
Drug Deliv; 2018 Nov; 25(1):1537-1545. PubMed ID: 29996687
[TBL] [Abstract][Full Text] [Related]
10. A Novel Approach of Daunorubicin Application on Formation of Proliferative Retinopathy Using a Porous Silicon Controlled Delivery System: Pharmacodynamics.
Hou H; Huffman K; Rios S; Freeman WR; Sailor MJ; Cheng L
Invest Ophthalmol Vis Sci; 2015 Apr; 56(4):2755-63. PubMed ID: 25829415
[TBL] [Abstract][Full Text] [Related]
11. Ocular silicon distribution and clearance following intravitreal injection of porous silicon microparticles.
Nieto A; Hou H; Sailor MJ; Freeman WR; Cheng L
Exp Eye Res; 2013 Nov; 116():161-8. PubMed ID: 24036388
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and characterization of tumor-targeted copolymer nanocarrier modified by transferrin.
Liu R; Wang Y; Li X; Bao W; Xia G; Chen W; Cheng J; Xu Y; Guo L; Chen B
Drug Des Devel Ther; 2015; 9():2705-19. PubMed ID: 26045659
[TBL] [Abstract][Full Text] [Related]
13. New model of proliferative vitreoretinopathy in rabbit for drug delivery and pharmacodynamic studies.
Moon SW; Sun Y; Warther D; Huffman K; Freeman WR; Sailor MJ; Cheng L
Drug Deliv; 2018 Jan; 25(1):600-610. PubMed ID: 29461171
[TBL] [Abstract][Full Text] [Related]
14. A sustained intravitreal drug delivery system with remote real time monitoring capability.
Hou H; Nieto A; Belghith A; Nan K; Li Y; Freeman WR; Sailor MJ; Cheng L
Acta Biomater; 2015 Sep; 24():309-21. PubMed ID: 26087110
[TBL] [Abstract][Full Text] [Related]
15. Construction of multifunctional porous silica nanocarriers for pH/enzyme-responsive drug release.
Qiu L; Zhang W; Wang S; Zhang X; Zhao Y; Cao L; Sun L
Mater Sci Eng C Mater Biol Appl; 2017 Dec; 81():485-491. PubMed ID: 28888002
[TBL] [Abstract][Full Text] [Related]
16. Sustained delivery of a HIF-1 antagonist for ocular neovascularization.
Iwase T; Fu J; Yoshida T; Muramatsu D; Miki A; Hashida N; Lu L; Oveson B; Lima e Silva R; Seidel C; Yang M; Connelly S; Shen J; Han B; Wu M; Semenza GL; Hanes J; Campochiaro PA
J Control Release; 2013 Dec; 172(3):625-33. PubMed ID: 24126220
[TBL] [Abstract][Full Text] [Related]
17. Suitability of porous silicon microparticles for the long-term delivery of redox-active therapeutics.
Wu EC; Andrew JS; Buyanin A; Kinsella JM; Sailor MJ
Chem Commun (Camb); 2011 May; 47(20):5699-701. PubMed ID: 21503283
[TBL] [Abstract][Full Text] [Related]
18. Enzyme/GSH/pH-responsive hyaluronic acid grafted porous silica nanocarriers bearing Ag
Hou J; Zhao Y; Sun L; Zou X
Carbohydr Polym; 2023 Apr; 305():120547. PubMed ID: 36737216
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and antitumor efficacy of daunorubicin-loaded magnetic nanoparticles.
Wang J; Chen B; Chen J; Cai X; Xia G; Liu R; Chen P; Zhang Y; Wang X
Int J Nanomedicine; 2011; 6():203-11. PubMed ID: 21445276
[TBL] [Abstract][Full Text] [Related]
20. Contrastive Studies of Cytarabine/Daunorubicin Dual-Loaded Liposomes Prepared by pH Gradient and Cu
Zhang J; Zhou L; Zhang Y; He H; Yin T; Gou J; Wang Y; Tang X
AAPS PharmSciTech; 2020 Nov; 21(8):325. PubMed ID: 33206247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
